ADC Therapeutics SA (NYSE:ADCT) Receives $7.50 Average Target Price from Analysts

Shares of ADC Therapeutics SA (NYSE:ADCT) have earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $7.50.

Several equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of ADC Therapeutics in a research note on Monday, April 15th. Guggenheim reiterated a “buy” rating on shares of ADC Therapeutics in a research note on Friday, April 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 price objective on shares of ADC Therapeutics in a research note on Thursday, March 14th.

ADC Therapeutics Stock Down 3.9 %

Shares of NYSE ADCT opened at $4.78 on Monday. ADC Therapeutics has a twelve month low of $0.36 and a twelve month high of $6.04. The stock’s 50 day moving average price is $4.65 and its 200-day moving average price is $2.65. The company has a market capitalization of $395.42 million, a PE ratio of -1.63 and a beta of 1.73.

ADC Therapeutics (NYSE:ADCT) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.56). ADC Therapeutics had a negative net margin of 344.15% and a negative return on equity of 1,313.37%. The firm had revenue of $16.79 million during the quarter, compared to analysts’ expectations of $16.58 million. As a group, research analysts expect that ADC Therapeutics will post -2.2 EPS for the current fiscal year.

Institutional Investors Weigh In On ADC Therapeutics

Several institutional investors have recently made changes to their positions in ADCT. Saxony Capital Management LLC bought a new position in shares of ADC Therapeutics in the fourth quarter worth $34,000. Acadian Asset Management LLC increased its stake in ADC Therapeutics by 613.8% in the third quarter. Acadian Asset Management LLC now owns 156,048 shares of the company’s stock valued at $138,000 after acquiring an additional 134,186 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in ADC Therapeutics by 7.1% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 70,636 shares of the company’s stock valued at $317,000 after acquiring an additional 4,700 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in ADC Therapeutics by 83.3% in the third quarter. Affinity Asset Advisors LLC now owns 1,100,000 shares of the company’s stock valued at $987,000 after acquiring an additional 500,000 shares during the last quarter. Finally, Redmile Group LLC increased its stake in ADC Therapeutics by 0.9% in the third quarter. Redmile Group LLC now owns 14,178,045 shares of the company’s stock valued at $12,718,000 after acquiring an additional 128,110 shares during the last quarter. Hedge funds and other institutional investors own 41.10% of the company’s stock.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.